Alimera Sciences

OverviewSuggest Edit

Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is focused on diseases affecting the back of the eye, or retina. It provides ILUVIEN (fluocinolone acetonide intravitreal implant) for the treatment of diabetic macular edema (DME).
TypePublic
Founded2003
HQAlpharetta, GA, US
Websitealimerasciences.com
Employee Ratings4.1
Overall CultureB-

Latest Updates

Employees (est.) (Jan 2020)122(-1%)
Job Openings19
Revenue (FY, 2020)$50.8 M(-5%)
Share Price (Jun 2022)$5.3(-4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Alimera Sciences

Ken Greene

Ken Greene

CSO
Rick Eiswirth

Rick Eiswirth

Director, President and Chief Executive Officer
Susan Caballa

Susan Caballa

Sr. Vice President, Regulatory & Medical Affairs
Brian Halak

Brian Halak

Director
Philip Ashman

Philip Ashman

Chief Operating Officer Senior Vice President, Commercial Operations Europe
Phil Jones

Phil Jones

Chief Financial Officer
Show more

Alimera Sciences Office Locations

Alimera Sciences has offices in Alpharetta, Berlin, Dublin 2, Lisboa and in 1 other location
Alpharetta, GA, US (HQ)
6120 Windward Pkwy #290
Berlin, DE
21 Cicerostraße
Dublin 2, IE
block c, Fitzwilliam Business Centre, 77 Sir John Rogerson's Quay, Dublin Docklands
Lisboa, PT
Avenida D. João II, 50 Edificio, R. do Mar Vermelho
Hampshire, GB
Wellesley Rd
Show all (5)

Alimera Sciences Financials and Metrics

Alimera Sciences Revenue

Alimera Sciences's revenue was reported to be $50.82 m in FY, 2020
USD

Revenue (FY, 2020)

50.8m

Net income (FY, 2020)

(5.3m)

EBIT (FY, 2020)

(501.0k)

Market capitalization (24-Jun-2022)

36.4m

Closing stock price (24-Jun-2022)

5.3

Cash (31-Dec-2020)

11.2m

EV

69.6m
Alimera Sciences's current market capitalization is $36.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.9m8.4m22.4m34.3m35.9m47.0m53.9m50.8m

Revenue growth, %

350%166%53%

Cost of goods sold

1.9m1.4m1.8m2.3m3.4m4.7m

Gross profit

9.0k7.0m20.7m32.0m32.5m42.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

179.0k758.0k2.1m2.2m2.4m3.9m5.8m6.9m5.8m9.6m8.3m6.6m10.4m9.8m9.8m10.9m11.1m12.9m10.9m12.9m14.5m10.0m12.5m

Cost of goods sold

11.0k57.0k564.0k376.0k372.0k283.0k376.0k634.0k378.0k556.0k486.0k587.0k769.0k1.0m1.3m1.1m965.0k1.6m

Gross profit

168.0k701.0k1.5m1.8m2.0m3.7m5.4m6.3m5.4m9.0m7.8m6.0m9.6m8.7m8.5m9.8m10.2m11.3m

Gross profit Margin, %

94%92%73%83%85%93%93%91%93%94%94%91%93%89%87%90%91%88%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

33.1m49.6m12.6m76.7m31.1m31.0m24.1m13.0m9.4m11.2m

Accounts Receivable

500.0k850.0k9.8m13.8m11.4m17.3m19.3m17.2m

Prepaid Expenses

692.0k2.0m3.5m3.2m2.7m2.3m2.1m2.6m3.7m

Inventories

719.0k1.8m1.7m1.6m446.0k1.5m2.4m1.4m2.7m
USDQ2, 2011

Financial Leverage

1.3 x
Show all financial metrics

Alimera Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Alimera Sciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Alimera Sciences Online and Social Media Presence

Embed Graph

Alimera Sciences Company Culture

  • Overall Culture

    B-

    77/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A

    88/100

Learn more on Comparably

Alimera Sciences News and Updates

Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update

Conference Call to be held the same day at 9:00am Eastern Time Conference Call to be held the same day at 9:00am Eastern Time

Alimera Sciences Reports Fourth Quarter and FY 2021 Results

Fourth Quarter Highlights:

Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference

ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that Rick Eiswirt…

Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences

ATLANTA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining bett…

Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors

ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of E…

Alimera Sciences Announces Third Quarter 2021 Financial Results

ATLANTA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results f…
Show more

Alimera Sciences Blogs

Alimera Sciences to Present at the Q1 Investor Summit Conference

Alimera Sciences to Present at the Q1 Investor Summit Conference

Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update

Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update

Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences

Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences

Alimera Sciences Announces First Quarter 2021 Financial Results

Alimera Sciences Announces First Quarter 2021 Financial Results

Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland

Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland

Alimera Sciences to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference

Alimera Sciences to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
Show more

Alimera Sciences Frequently Asked Questions

  • When was Alimera Sciences founded?

    Alimera Sciences was founded in 2003.

  • Who are Alimera Sciences key executives?

    Alimera Sciences's key executives are Ken Greene, Rick Eiswirth and Susan Caballa.

  • How many employees does Alimera Sciences have?

    Alimera Sciences has 122 employees.

  • What is Alimera Sciences revenue?

    Latest Alimera Sciences annual revenue is $50.8 m.

  • What is Alimera Sciences revenue per employee?

    Latest Alimera Sciences revenue per employee is $416.6 k.

  • Who are Alimera Sciences competitors?

    Competitors of Alimera Sciences include BeyondSpring, Hisamitsu Pharmaceutical and Strides Pharma.

  • Where is Alimera Sciences headquarters?

    Alimera Sciences headquarters is located at 6120 Windward Pkwy #290, Alpharetta.

  • Where are Alimera Sciences offices?

    Alimera Sciences has offices in Alpharetta, Berlin, Dublin 2, Lisboa and in 1 other location.

  • How many offices does Alimera Sciences have?

    Alimera Sciences has 5 offices.